Insulin, Metformin , Oral Hypoglycemic agents pharmacology notes in details
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Katzung's Pharmacology has a dedicated "Antidiabetic Drugs" section. Let me read that alongside the Goldman-Cecil and other key sources in parallel.
Reading File
Reading File
Reading File
Now let me read Katzung's Chapter 41 which has the full antidiabetic drugs pharmacology section, and Goldman-Cecil's dedicated diabetes treatment block.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I found Lippincott Pharmacology — let me read it along with the Goldman-Cecil block for oral hypoglycemics and the Ganong physiology section.
Reading File
Reading File
Reading File
I now have rich data from multiple textbooks. Let me read the Lippincott Pharmacology diabetes chapter directly:
Reading File
Reading File
I need to find the actual Lippincott chapter 24 on diabetes/insulin pharmacology content. Let me search from offset 2000 onward where the chapter content likely sits:
Reading File
I have sufficient information from multiple authoritative textbooks (Katzung, Goldman-Cecil, Ganong, Lippincott) to compile comprehensive pharmacology notes. Let me now compose the detailed notes.
📚 Pharmacology Notes: Insulin, Metformin & Oral Hypoglycemic Agents
Sources: Katzung's Basic & Clinical Pharmacology 16e, Goldman-Cecil Medicine, Lippincott Illustrated Reviews Pharmacology, Ganong's Review of Medical Physiology 26e
🔵 PART 1: INSULIN
Structure & Biosynthesis
Insulin is a polypeptide hormone secreted by pancreatic β cells (islets of Langerhans). It consists of two chains:
- A chain: 21 amino acids
- B chain: 30 amino acids
- Linked by two disulfide bridges
Biosynthesis sequence: Preproinsulin → Proinsulin → Insulin + C-peptide (equimolar, clinically used to assess endogenous secretion)
Mechanism of Insulin Secretion
Glucose enters the β cell via GLUT2 transporters → undergoes glycolysis → raises ATP/ADP ratio → closes ATP-sensitive K⁺ channels (K_ATP) → membrane depolarization → opens voltage-gated Ca²⁺ channels → Ca²⁺ influx → exocytosis of insulin granules
Potentiators of secretion include:
- Amino acids (arginine, leucine), β-keto acids
- GLP-1, GIP (incretins)
- Acetylcholine (M3 receptors), β₂-adrenergic stimulation
- Increased cAMP (glucagon, β-agonists, theophylline)
Inhibitors: α₂-adrenergic stimulation (catecholamines, net effect), somatostatin, galanin
Mechanism of Action of Insulin
Insulin binds the insulin receptor (tyrosine kinase receptor):
- Receptor autophosphorylation → activates IRS-1 and IRS-2 (insulin receptor substrates)
- Activates PI3K → PDK1 → Akt (PKB) pathway
- Triggers translocation of GLUT-4 transporters to cell surface (muscle, adipose)
- Promotes glycogen synthesis (inhibits glycogen phosphorylase, activates glycogen synthase)
- Promotes protein synthesis, lipogenesis, and inhibits lipolysis
Physiological Effects
| Tissue | Effect |
|---|---|
| Liver | ↑ glycogen synthesis, ↑ lipogenesis, ↓ gluconeogenesis, ↓ glycogenolysis |
| Muscle | ↑ glucose uptake (GLUT-4), ↑ glycogen & protein synthesis |
| Adipose | ↑ glucose uptake (GLUT-4), ↑ lipogenesis, ↓ lipolysis (inhibits hormone-sensitive lipase) |
| All cells | ↑ K⁺ uptake (drives K⁺ intracellularly — used in hyperkalemia treatment) |
Insulin Preparations
Classified by onset, peak, and duration of action:
🔴 Rapid-Acting (Insulin Analogs)
| Preparation | Onset | Peak | Duration |
|---|---|---|---|
| Insulin lispro | 5–15 min | 30–90 min | 3–5 h |
| Insulin aspart | 5–15 min | 30–90 min | 3–5 h |
| Insulin glulisine | 5–15 min | 30–90 min | 3–5 h |
MOA modification: In lispro, B28-B29 proline-lysine are inverted → reduces self-aggregation → faster absorption from SC site
🟡 Short-Acting (Regular Insulin)
| Preparation | Onset | Peak | Duration |
|---|---|---|---|
| Regular insulin | 30–60 min | 2–4 h | 5–8 h |
Given 30 min before meals. Only insulin that can be given IV (used in DKA, hyperkalemia, surgical patients).
🟢 Intermediate-Acting
| Preparation | Onset | Peak | Duration |
|---|---|---|---|
| NPH (isophane) | 1–2 h | 6–10 h | 16–24 h |
NPH = Neutral Protamine Hagedorn — protamine added to delay absorption. Cloudy suspension.
🔵 Long-Acting (Basal Analogs)
| Preparation | Onset | Peak | Duration |
|---|---|---|---|
| Insulin glargine | 1–2 h | Peakless | ~24 h |
| Insulin detemir | 1–2 h | Minimal | 18–24 h |
| Insulin degludec | 1–2 h | Peakless | >42 h |
Glargine mechanism: Acidic pH (4.0) in vial → at neutral SC pH, forms microprecipitate → slow absorption → stable basal coverage. Cannot be mixed with other insulins.
🟣 Premixed Combinations
- 70/30: 70% NPH + 30% Regular
- 75/25: 75% neutral protamine lispro + 25% lispro
Clinical Uses of Insulin
- Type 1 Diabetes Mellitus (absolute indication — absolute insulin deficiency)
- Type 2 DM (when oral agents fail, or HbA1c very high)
- Diabetic Ketoacidosis (DKA) — IV regular insulin
- Hyperkalemia — drives K⁺ into cells (given with dextrose)
- Gestational diabetes (preferred over most oral agents)
- Critically ill patients (surgical ICU — tight glucose control)
Insulin Regimens
- Basal-bolus: Basal (long-acting once daily) + Bolus (rapid-acting with each meal) — most physiological
- Basal only: For T2DM inadequately controlled on oral agents
- Split-mixed: NPH + Regular twice daily (older regimen)
Adverse Effects of Insulin
| Adverse Effect | Details |
|---|---|
| Hypoglycemia | Most dangerous; risk ↑ with excess dose, missed meals, exercise, alcohol |
| Weight gain | Anabolic effect; lipogenesis |
| Lipodystrophy | Lipoatrophy (old animal insulins) or lipohypertrophy (repeated injection at same site) |
| Hypokalemia | K⁺ shift into cells |
| Edema | Na⁺ retention (acute insulin therapy) |
| Allergic reactions | Rare with human insulin |
| Somogyi effect | Rebound hyperglycemia after nocturnal hypoglycemia |
| Dawn phenomenon | Early morning hyperglycemia from GH surge (physiological) |
🟠 PART 2: METFORMIN
Drug Class
Biguanide — the only clinically used biguanide (phenformin/buformin withdrawn due to severe lactic acidosis risk)
Mechanism of Action
Metformin's primary actions:
- ↓ Hepatic gluconeogenesis (main effect) — inhibits mitochondrial complex I → ↓ ATP/ADP ratio → activates AMPK → inhibits PEPCK, G6Pase transcription → ↓ gluconeogenesis
- ↑ Peripheral insulin sensitivity — enhances insulin-stimulated glucose uptake in muscle
- ↓ Intestinal glucose absorption (minor contribution)
- ↓ Hepatic glycogenolysis
AMPK activation by metformin mimics the state of cellular energy depletion and has pleiotropic metabolic benefits beyond glycemic control.
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Bioavailability | ~50–60% (intestinal absorption) |
| Protein binding | Negligible |
| Metabolism | NOT hepatically metabolized — excreted unchanged |
| Elimination | Renal tubular secretion (via OCT2 transporter) |
| Half-life | ~6 hours (plasma); ~17 hours (whole blood) |
Clinical Effects
- Reduces HbA1c by 1.0–1.5%
- Does NOT cause hypoglycemia (no effect on insulin secretion)
- Weight neutral or promotes modest weight loss
- Reduces cardiovascular events and mortality in obese T2DM patients (UKPDS evidence)
- Preferred first-line therapy for Type 2 DM — Lippincott, Goldman-Cecil
Dosing
- Start low: 500 mg once or twice daily with meals
- Titrate slowly to reduce GI side effects
- Maximum dose: 2550 mg/day (limited by GI tolerance and renal function)
- Extended-release formulation improves GI tolerability
Adverse Effects
| Adverse Effect | Details |
|---|---|
| GI symptoms | Nausea, diarrhea, bloating, anorexia — most common; dose-related; improve with time |
| Lactic acidosis | Rare but potentially fatal; risk ↑ in renal failure, hepatic dysfunction, hypoxia, sepsis, alcoholism |
| Vitamin B₁₂ deficiency | Long-term use → ↓ ileal absorption of B₁₂ (competes with intrinsic factor-B₁₂ complex) → worsening neuropathy → periodic B₁₂ testing recommended |
| Metallic taste | Common, transient |
Contraindications
| Contraindication | Reason |
|---|---|
| eGFR < 30 mL/min | Drug accumulates → lactic acidosis risk |
| Iodinated contrast agents | Hold temporarily (48 h before and after) — risk of acute kidney injury with contrast → drug accumulation |
| Hepatic failure | Impaired lactate clearance |
| Acute illness with dehydration | Renal hypoperfusion |
| Heavy alcohol use | Potentiates lactic acidosis |
🟢 PART 3: OTHER ORAL HYPOGLYCEMIC AGENTS
3.1 SULFONYLUREAS (First-generation & Second-generation)
Mechanism of Action
Sulfonylureas bind to the SUR1 subunit of K_ATP channels on β-cell membrane → block K⁺ efflux → membrane depolarization → Ca²⁺ influx → insulin secretion (glucose-independent)
- Require functional β cells — ineffective in T1DM or after pancreatectomy
- Act independent of plasma glucose levels → risk of hypoglycemia even in euglycemia
Drug List
1st Generation (older, more side effects):
- Tolbutamide, Chlorpropamide, Tolazamide, Acetohexamide
2nd Generation (preferred — more potent, fewer interactions):
- Glipizide — short-acting, preferred in elderly/renal disease
- Glyburide (Glibenclamide) — active metabolites → higher hypoglycemia risk
- Glimepiride — once daily, lowest hypoglycemia risk among SUs
- Gliclazide — cardioprotective profile
Pharmacokinetics (2nd gen)
- Good oral bioavailability
- Hepatically metabolized (CYP2C9)
- Glipizide: inactive metabolites; Glyburide: active metabolites (avoid in renal/elderly)
- Highly protein-bound — drug interactions with NSAIDs, warfarin, sulfonamides (displace → ↑ effect)
Clinical Effects
- Reduce HbA1c by 1.0–2.0%
- ↑ Weight (anabolic — insulin secretion)
Adverse Effects
| Effect | Details |
|---|---|
| Hypoglycemia | Most important; prolonged with long-acting agents (glyburide) |
| Weight gain | Due to hyperinsulinemia |
| Hyponatremia (SIADH) | Chlorpropamide (1st gen) potentiates ADH |
| Disulfiram-like reaction | Chlorpropamide with alcohol |
| Hematological | Agranulocytosis, hemolytic anemia (rare) |
| Photosensitivity | Chlorpropamide |
3.2 MEGLITINIDES (Non-Sulfonylurea Insulin Secretagogues)
Drugs
- Repaglinide — also has PPAR-γ activity
- Nateglinide — derivative of D-phenylalanine
Mechanism
Bind to different site on SUR1 of K_ATP channel (same ultimate effect as sulfonylureas) → ↑ insulin secretion
Key Features
- Rapid-acting, short-duration — taken just before each meal (→ control postprandial glucose)
- Useful when meal timing is irregular
- Shorter hypoglycemia risk window than sulfonylureas
- Repaglinide hepatically metabolized → usable in renal disease
- Nateglinide: only effective in presence of glucose (glucose-dependent to some extent)
3.3 BIGUANIDES — Metformin (covered above)
3.4 THIAZOLIDINEDIONES (TZDs / Glitazones)
Drugs
- Pioglitazone (currently used)
- Rosiglitazone (restricted — CV concerns)
- Troglitazone (withdrawn — hepatotoxicity)
Mechanism
Bind to and activate PPARγ (Peroxisome Proliferator-Activated Receptor-γ) — a nuclear transcription factor in adipocytes → regulates genes involved in glucose and lipid metabolism → ↑ insulin sensitivity in adipose tissue, muscle, and liver
- ↑ GLUT-4 expression
- ↑ Adiponectin (anti-inflammatory, insulin-sensitizing adipokine)
- ↓ Free fatty acids
- ↓ Hepatic gluconeogenesis
Clinical Effects
- Reduce HbA1c by 0.5–1.4%
- Do NOT cause hypoglycemia (no insulin secretion)
- Pioglitazone: favorable lipid profile (↑ HDL, ↓ TG)
Adverse Effects
| Effect | Details |
|---|---|
| Fluid retention / edema | ↑ Na⁺ reabsorption → fluid retention |
| Weight gain | ↑ Adipogenesis |
| Heart failure exacerbation | Contraindicated in NYHA Class III–IV HF |
| Bone fractures | ↑ risk in women (peripheral bones) |
| Bladder cancer risk | Pioglitazone (long-term use; controversial) |
| Hepatotoxicity | Troglitazone (withdrawn); monitor LFTs with others |
| Anemia / hemodilution | Plasma volume expansion |
3.5 ALPHA-GLUCOSIDASE INHIBITORS
Drugs
- Acarbose, Miglitol, Voglibose
Mechanism
Competitively inhibit intestinal α-glucosidase enzymes (maltase, sucrase, dextrinase) at the brush border of the small intestine → delay carbohydrate digestion and absorption → blunt postprandial glucose rise
Clinical Effects
- Reduce HbA1c by 0.5–0.8% (modest)
- No hypoglycemia (when used alone)
- May reduce postprandial cardiovascular risk (STOP-NIDDM trial)
Adverse Effects
- GI: Flatulence, bloating, diarrhea, abdominal cramps (undigested carbohydrates fermented in colon) — dose-limiting
- Liver toxicity (rare, high-dose acarbose)
- Note: If hypoglycemia occurs while on acarbose + sulfonylurea → treat with glucose (dextrose), NOT sucrose (sucrose hydrolysis impaired)
3.6 DPP-4 INHIBITORS (Gliptins)
Drugs
- Sitagliptin, Saxagliptin, Vildagliptin, Alogliptin, Linagliptin
Mechanism
Inhibit Dipeptidyl Peptidase-4 (DPP-4) enzyme → prevents degradation of GLP-1 and GIP (incretin hormones) → prolongs incretin action → ↑ glucose-dependent insulin secretion → ↓ glucagon secretion
- Glucose-dependent → minimal hypoglycemia risk
Clinical Effects
- Reduce HbA1c by 0.5–0.8%
- Weight neutral
- Linagliptin: no dose adjustment required in renal failure (biliary excretion)
Adverse Effects
- Nasopharyngitis, upper respiratory infections
- Pancreatitis (rare but black box warning)
- Heart failure hospitalization risk — saxagliptin (SAVOR-TIMI trial); class concern
- Arthralgia (rare, immune-mediated)
3.7 GLP-1 RECEPTOR AGONISTS
Drugs
- Short-acting (daily): Exenatide (BID), Liraglutide (OD)
- Long-acting (weekly): Semaglutide, Dulaglutide, Exenatide XR
Mechanism
GLP-1 receptor agonists (peptide analogs resistant to DPP-4 degradation) → bind GLP-1 receptors → ↑ glucose-dependent insulin secretion → ↓ glucagon → slow gastric emptying → ↑ satiety (central effect on hypothalamus)
Clinical Effects
- Reduce HbA1c by 0.8–1.5%
- Significant weight loss (1.5–6 kg) — best among oral/injectable antidiabetics
- Cardiovascular benefit: Liraglutide (LEADER trial), Semaglutide (SUSTAIN-6) → ↓ MACE (CV death, MI, stroke)
- Approved for weight management (semaglutide — Ozempic/Wegovy)
Adverse Effects
- Nausea, vomiting, diarrhea (common, especially initially)
- Pancreatitis (black box warning)
- Thyroid C-cell tumors (rodent data → contraindicated with personal/family history of MTC or MEN2)
- Injection site reactions
3.8 SGLT-2 INHIBITORS (Gliflozins)
Drugs
- Empagliflozin, Dapagliflozin, Canagliflozin, Ertugliflozin
Mechanism
Inhibit Sodium-Glucose Cotransporter 2 (SGLT2) in the S1 segment of renal proximal tubule → block ~90% of filtered glucose reabsorption → glucosuria (~70–80 g glucose/day)
Also: natriuresis → ↓ blood pressure and preload
Clinical Effects
- Reduce HbA1c by 0.5–1.0%
- ↓ Body weight 1–3 kg (caloric loss via urine)
- ↓ Blood pressure (5–7 mmHg)
- Cardiovascular benefit: empagliflozin (EMPA-REG OUTCOME) → ↓ CV death, HF hospitalization in T2DM + CVD
- Renoprotective: ↓ albuminuria, slow eGFR decline → approved in CKD (dapagliflozin)
- Approved in Heart Failure (empagliflozin for HFrEF and HFpEF)
Adverse Effects
| Effect | Details |
|---|---|
| Genital mycotic infections | Candidal vulvovaginitis / balanitis — most common |
| UTI | Glucosuria promotes bacterial growth |
| Diabetic ketoacidosis | Even with normal glucose (euglycemic DKA) — low insulin → ↑ glucagon → ↑ ketogenesis |
| Volume depletion / hypotension | Especially in elderly / loop diuretics |
| Fournier's gangrene | Rare — necrotizing fasciitis of perineum |
| Canagliflozin | ↑ fracture risk, ↑ toe/foot amputations |
| Efficacy ↓ with eGFR < 45 | Requires GFR to filter glucose |
📊 COMPARISON SUMMARY TABLE
| Drug Class | MOA | HbA1c ↓ | Hypoglycemia | Weight | Key Advantage |
|---|---|---|---|---|---|
| Insulin | Direct replacement | Variable | Yes | ↑↑ | Works in all types |
| Metformin | ↓ hepatic gluconeogenesis (AMPK) | 1.0–1.5% | No | Neutral/↓ | First-line; CV benefit |
| Sulfonylureas | Block K_ATP → ↑ insulin secretion | 1.0–2.0% | Yes | ↑ | Effective; cheap |
| Meglitinides | Same as SU (diff site); rapid | 0.5–1.5% | Low | ↑ | Postprandial control |
| TZDs | PPARγ activation → ↑ sensitivity | 0.5–1.4% | No | ↑↑ | Insulin sensitizer |
| α-GI | ↓ carbohydrate absorption | 0.5–0.8% | No | Neutral | Postprandial |
| DPP-4i | ↑ Incretins (GLP-1/GIP) | 0.5–0.8% | No | Neutral | Well-tolerated |
| GLP-1 RA | GLP-1 receptor agonism | 0.8–1.5% | No | ↓↓ | CV/weight benefit |
| SGLT-2i | ↑ Renal glucose excretion | 0.5–1.0% | No | ↓ | CV/renal protection |
🎯 CLINICAL DECISION POINTS
Type 2 DM treatment algorithm (current guidelines):
- First-line: Metformin (unless contraindicated)
- + ASCVD / HF / CKD: Add SGLT-2i or GLP-1 RA regardless of HbA1c
- + Need weight loss: GLP-1 RA preferred
- + Severe renal impairment (eGFR < 30): Use linagliptin (no renal dose adjustment)
- Insulin: Type 1 DM (mandatory), T2DM with HbA1c > 10–11%, acute illness, surgery, DKA
- Pregnancy: Insulin preferred; metformin/glyburide used in some centers
Remember:
- Sulfonylureas + insulin = highest hypoglycemia risk
- SGLT-2i = glucose-dependent → no hypoglycemia, but euglycemic DKA possible
- Metformin + contrast: hold 48 h before/after procedure
- Glyburide: avoid in elderly (prolonged active metabolites)
- Pioglitazone: avoid in HF, bladder cancer risk
- Liraglutide/semaglutide: contraindicated in personal/family history of medullary thyroid carcinoma
References: Katzung's Basic and Clinical Pharmacology 16e (Ch. 13, 41), Goldman-Cecil Medicine International Edition, Lippincott Illustrated Reviews Pharmacology, Ganong's Review of Medical Physiology 26e
This is a shared conversation. Sign in to Orris to start your own chat.